• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by EDAP TMS S.A.

    1/13/25 7:10:57 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    6-K 1 f6k_011325.htm FORM 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

     

    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    January 13, 2025

     

    Commission File Number: 0-29374

     

    EDAP TMS S.A.
    Parc Activite La Poudrette Lamartine
    4/6 Rue du Dauphine
    69120 Vaulx-en-Velin - France

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F [ x]      Form 40-F [  ]

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: January 13, 2025

     

    EDAP TMS S.A.

     

     

     

    /s/ KEN MOBECK
    KEN MOBECK
    CHIEF FINANCIAL OFFICER

     

     

     

     

    EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

     

    Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems

     

    Record U.S. Fourth Quarter Focal One System Sales

     

    Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30%

     

    AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal OneÒ System sales for the fourth quarter of calendar year 2024. The Company experienced robust demand for its Focal One Robotic HIFU technology, reporting preliminary record fourth quarter of 11 Focal One Systems.

     

    “Our strong fourth quarter performance reflects the growing adoption of our industry-leading Focal One Robotic HIFU technology platform, which is fundamentally transforming how urologists manage prostate cancer,” said Ryan Rhodes, Chief Executive Officer of EDAP. “The number of Focal One procedures also continues to grow rapidly, underscoring the practice changing dynamics taking place as Focal One Robotic HIFU becomes a mainstream treatment option for patients with prostate cancer. As Focal One continues to grow, we also expect the recent publication of the groundbreaking HIFI study in the prestigious scientific journal, European Urology, will further drive awareness and adoption.”

     

    “Entering 2025, our Focal One pipeline remains robust and strong, and we continue to expect a growing number of urology practices to adopt Focal One for men diagnosed with prostate cancer.”

     

    The above information is preliminary and subject to completion of quarter-end financial reporting processes and reviews. EDAP expects to release final fourth quarter financial results in March.

     

    About EDAP TMS SA

     

    A recognized leader in the robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.

     

    Forward-Looking Statements

     

    In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

     

     

     

     

    Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

     

    Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

     

    Company Contact
    Blandine Confort
    Investor Relations / Legal Affairs
    EDAP TMS SA
    +33 4 72 15 31 50
    [email protected]

     

    Investor Contact
    John Fraunces
    LifeSci Advisors, LLC
    (917) 355-2395
    [email protected]

     

     

     

    Get the next $EDAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    5/15/2025Overweight → Neutral
    Piper Sandler
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    SEC Filings

    See more
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      6/2/25 4:35:11 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      5/15/25 7:05:37 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 filed by EDAP TMS S.A.

      S-8 - EDAP TMS SA (0001041934) (Filer)

      5/14/25 4:36:27 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EDAP TMS SA downgraded by Piper Sandler

      Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral

      5/15/25 1:10:07 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP TMS SA downgraded by Jefferies with a new price target

      Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

      4/4/25 8:36:35 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on EDAP TMS SA with a new price target

      Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

      11/1/22 6:28:24 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • EDAP to Present at the Jefferies Global Healthcare Conference

      AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.  Presentation details: Date:Thursday, June 5th Time:4:20-4:50 PM ET Webcast:https://wsw.com/webcast/jeff319/edap/1824368 The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here. About EDAP TMS SA A recognized leader in robotic energy-based therapies, EDAP TMS develops, ma

      5/27/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Reports First Quarter 2025 Financial Results

                Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World's First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the first quarter of 2025. "Demand for Focal One remai

      5/15/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care